{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:11:24Z","timestamp":1753881084944,"version":"3.41.2"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI111435","R44AI138903","T32AI7384","HHSN272201600024C"],"award-info":[{"award-number":["R01AI111435","R44AI138903","T32AI7384","HHSN272201600024C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"HHS | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R44EB011274"],"award-info":[{"award-number":["R44EB011274"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R44GM103053"],"award-info":[{"award-number":["R44GM103053"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2023,3,23]]},"abstract":"<jats:p>While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing.<\/jats:p>","DOI":"10.1128\/jcm.01478-22","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:01:36Z","timestamp":1675951296000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort"],"prefix":"10.1128","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7388","authenticated-orcid":true,"given":"Rehan R.","family":"Syed","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-0574","authenticated-orcid":true,"given":"Donald G.","family":"Catanzaro","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-2100","authenticated-orcid":true,"given":"Rebecca E.","family":"Colman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Cooney","sequence":"additional","affiliation":[{"name":"Akonni Biosystems, Inc., Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Linger","sequence":"additional","affiliation":[{"name":"Akonni Biosystems, Inc., Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Kukhtin","sequence":"additional","affiliation":[{"name":"Akonni Biosystems, Inc., Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca C.","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Akonni Biosystems, Inc., Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Norville","sequence":"additional","affiliation":[{"name":"Akonni Biosystems, Inc., Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeriu","family":"Crudu","sequence":"additional","affiliation":[{"name":"Phthisiopneumology Institute, Chi\u0219in\u0103u, Republic of Moldova"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Ciobanu","sequence":"additional","affiliation":[{"name":"Phthisiopneumology Institute, Chi\u0219in\u0103u, Republic of Moldova"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Codreanu","sequence":"additional","affiliation":[{"name":"Phthisiopneumology Institute, Chi\u0219in\u0103u, Republic of Moldova"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-6396","authenticated-orcid":true,"given":"Marva","family":"Seifert","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Hillery","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Chiles","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Catanzaro","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy C.","family":"Rodwell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report 2022.","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. 2022. Global tuberculosis report 2022. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","volume-title":"The End TB Strategy.","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. The End TB Strategy. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_4_2","volume-title":"WHO operational handbook on tuberculosis. Module 3: diagnosis\u2014rapid diagnostics for tuberculosis detection, 2021 update.","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. WHO operational handbook on tuberculosis. Module 3: diagnosis\u2014rapid diagnostics for tuberculosis detection, 2021 update. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_5_2","volume-title":"WHO announces updated definitions of extensively drug-resistant tuberculosis.","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. WHO announces updated definitions of extensively drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_6_2","volume-title":"Fact sheet: tuberculosis.","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. Fact sheet: tuberculosis. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis."},{"key":"e_1_3_3_7_2","volume-title":"Surveillance definitions for extensively drug resistant (XDR) and pre-XDR tuberculosis.","author":"Langer AJ","year":"2022","unstructured":"Langer AJ, Starks AM. 2022. Surveillance definitions for extensively drug resistant (XDR) and pre-XDR tuberculosis. Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/tb\/publications\/letters\/2022\/surv-def-xdr.html. Accessed 1 August 2022."},{"key":"e_1_3_3_8_2","volume-title":"Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance.","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10544-011-9584-9"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01652-17"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1039\/c8lc01404c"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2022.100304"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01417-20"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2196\/26748"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199869"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.9b05853"},{"key":"e_1_3_3_17_2","volume-title":"Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs.","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_18_2","volume-title":"Updated interim critical concentrations for first-line and second-line DST (as of May 2012).","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. 2012. Updated interim critical concentrations for first-line and second-line DST (as of May 2012). World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0650-x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800474"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(21)00301-3"},{"key":"e_1_3_3_22_2","volume-title":"Stata statistical software: release 17.","author":"StataCorp","year":"2021","unstructured":"StataCorp. 2021. Stata statistical software: release 17. StataCorp LLC, College Station, TX."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz106"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00626-2020"},{"key":"e_1_3_3_25_2","volume-title":"TB\/HIV co-infections up 40% across Europe over the last five years.","author":"United Nations Moldova","year":"2017","unstructured":"United Nations Moldova. 2017. TB\/HIV co-infections up 40% across Europe over the last five years. United Nations Moldova, Chi\u0219in\u0103u, Republic of Moldova."},{"key":"e_1_3_3_26_2","volume-title":"Tuberculosis country work summary: Republic of Moldova.","author":"World Health Organization Regional Office for Europe","year":"2012","unstructured":"World Health Organization Regional Office for Europe. 2012. Tuberculosis country work summary: Republic of Moldova. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907847"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw035"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201804-0654OC"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-015-0566-6"},{"key":"e_1_3_3_31_2","volume-title":"Target product profile for next-generation drug-susceptibility testing at peripheral centres.","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. Target product profile for next-generation drug-susceptibility testing at peripheral centres. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01599-17"},{"key":"e_1_3_3_33_2","volume-title":"Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine).","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02314-20"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2014.07.019"},{"key":"e_1_3_3_36_2","volume-title":"Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis.","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01478-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01478-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T13:04:35Z","timestamp":1679576675000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01478-22"}},"subtitle":[],"editor":[{"given":"Christine Y.","family":"Turenne","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,23]]}},"alternative-id":["10.1128\/jcm.01478-22"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01478-22","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"type":"print","value":"0095-1137"},{"type":"electronic","value":"1098-660X"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"2022-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01478-22"}}